Liquid biopsy as a monitoring tool for the benefit of chemotherapy-immunotherapy in aNSCLC

Bookmark and Share
Published: 24 Oct 2018
Views: 1983
Dr Laura Bonanno - University of Padova, Padova, Italy

Dr Laura Bonanno speaks with ecancer at ESMO 2018 in Munich about results from a study on using liquid biopsy as a tool to monitor and predict clinical benefit from chemotherapy and immunotherapy in aNSCLC.

Dr Bonanno states that it was possible to predict the benefit from the systemic treatment at early time points.

For more lung cancer news from the conference, watch Dr Enriqueta Felip summarise her highlights.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.